within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BX13_RosuvastatinPerindoprilAndIndapa;

model RosuvastatinPerindoprilAndIndapa
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 4.166666666666667e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 600);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>RosuvastatinPerindoprilAndIndapamide</td></tr><tr><td>ATC code:</td><td>C10BX13</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination medication containing rosuvastatin (a statin used to lower cholesterol), perindopril (an ACE inhibitor used for hypertension), and indapamide (a thiazide-like diuretic for hypertension and heart failure). Used for cardiovascular risk reduction and hypertension control. This combination is approved and is marketed in some countries.</p><h4>Pharmacokinetics</h4><p>No published studies currently available reporting pharmacokinetic parameters for the fixed-dose combination (FDC) of rosuvastatin/perindopril/indapamide as triple therapy. The following parameters are estimated based on published PK data of the individual components in healthy adult subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C10BX13 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RosuvastatinPerindoprilAndIndapa;
